181 related articles for article (PubMed ID: 30073478)
1. Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization.
Zhong BY; Ni CF; Yin GW; Chen L; Zhu HD; Guo JH; He SC; Deng G; Zhang Q; Li PC; Yu H; Teng GJ
Cardiovasc Intervent Radiol; 2018 Dec; 41(12):1867-1876. PubMed ID: 30073478
[TBL] [Abstract][Full Text] [Related]
2. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.
Yau T; Tang VY; Yao TJ; Fan ST; Lo CM; Poon RT
Gastroenterology; 2014 Jun; 146(7):1691-700.e3. PubMed ID: 24583061
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy.
Sohn JH; Duran R; Zhao Y; Fleckenstein F; Chapiro J; Sahu S; Schernthaner RE; Qian T; Lee H; Zhao L; Hamilton J; Frangakis C; Lin M; Salem R; Geschwind JF
Clin Gastroenterol Hepatol; 2017 May; 15(5):746-755.e4. PubMed ID: 27847278
[TBL] [Abstract][Full Text] [Related]
4. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.
Xiang X; Zhong JH; Wang YY; You XM; Ma L; Xiang BD; Li LQ
Clin Transl Oncol; 2017 Jul; 19(7):891-897. PubMed ID: 28160206
[TBL] [Abstract][Full Text] [Related]
5. Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective.
Li JW; Goh BG; Chang PE; Tan CK
World J Gastroenterol; 2017 Jun; 23(22):4054-4063. PubMed ID: 28652658
[TBL] [Abstract][Full Text] [Related]
6. BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy.
Longo L; Rodrigues de Freitas LB; Santos D; Grivicich I; Álvares-da-Silva MR
Am J Clin Oncol; 2019 May; 42(5):466-471. PubMed ID: 30913090
[TBL] [Abstract][Full Text] [Related]
7. Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology.
Liu PH; Hsu CY; Lee YH; Su CW; Hsia CY; Huang YH; Chiou YY; Lin HC; Huo TI
Medicine (Baltimore); 2015 Oct; 94(41):e1772. PubMed ID: 26469917
[TBL] [Abstract][Full Text] [Related]
8. HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival.
Wallace MC; Huang Y; Preen DB; Garas G; Adams LA; MacQuillan G; Tibballs J; Ferguson J; Samuelson S; Jeffrey GP
Dig Dis Sci; 2017 Aug; 62(8):2182-2192. PubMed ID: 28547649
[TBL] [Abstract][Full Text] [Related]
9. Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms.
Lee YS; Seo YS; Kim JH; Lee J; Kim HR; Yoo YJ; Kim TS; Kang SH; Suh SJ; Joo MK; Jung YK; Lee BJ; Yim HJ; Yeon JE; Kim JS; Park JJ; Um SH; Bak YT; Byun KS
Gut Liver; 2018 Jan; 12(1):94-101. PubMed ID: 28873509
[TBL] [Abstract][Full Text] [Related]
10. Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort.
Yan X; Fu X; Cai C; Zi X; Yao H; Qiu Y
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1180-6. PubMed ID: 26067223
[TBL] [Abstract][Full Text] [Related]
11. Validity of the Barcelona Clinic Liver Cancer and Hong Kong Liver Cancer staging systems for hepatocellular carcinoma in Singapore.
Selby LK; Tay RX; Woon WW; Low JK; Bei W; Shelat VG; Pang TC; Junnarkar SP
J Hepatobiliary Pancreat Sci; 2017 Mar; 24(3):143-152. PubMed ID: 28012284
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoembolization.
Zhong BY; Jiang JQ; Sun JH; Huang JT; Wang WD; Wang Q; Ding WB; Zhu XL; Ni CF
J Clin Transl Hepatol; 2023 Nov; 11(6):1321-1328. PubMed ID: 37719966
[TBL] [Abstract][Full Text] [Related]
13. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?
Kim KM; Sinn DH; Jung SH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Liver Int; 2016 Oct; 36(10):1490-7. PubMed ID: 26936471
[TBL] [Abstract][Full Text] [Related]
14. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study.
Zhong JH; Peng NF; You XM; Ma L; Xiang X; Wang YY; Gong WF; Wu FX; Xiang BD; Li LQ
Oncotarget; 2017 Mar; 8(11):18296-18302. PubMed ID: 28407686
[TBL] [Abstract][Full Text] [Related]
15. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients.
Heinrich S; Sprinzl M; Schmidtmann I; Heil E; Koch S; Czauderna C; Heinrich B; Philippe P Diggs L; Wörns MA; Kloeckner R; Galle PR; Marquardt JU; Weinmann A
United European Gastroenterol J; 2020 May; 8(4):444-452. PubMed ID: 32213028
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the Hong Kong Liver Cancer Staging System in Europe.
Kolly P; Reeves H; Sangro B; Knöpfli M; Candinas D; Dufour JF
Liver Int; 2016 Jun; 36(6):911-7. PubMed ID: 26677809
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
19. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
20. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
